# Ambit Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ambit-biosciences

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.ambitbio.com
- Total disclosed funding: $159M
- Latest round: Series E (May 1, 2013)
- Investors on record: 16

## About

Ambit Biosciences Inc. is a biopharmaceutical company specializing in developing targeted therapies for oncology and inflammatory diseases, focusing particularly on innovative treatments for acute myeloid leukemia.Founded in 2000 and headquartered in San Diego, US, Ambit Biosciences Inc. focuses on the discovery and development of targeted therapies. In May 2013, the company raised USD 65 mn in its IPO and was later acquired by Daiichi Sankyo Company for USD 410 mn in September 2014. The company has executed 13 deals as of the latest available data.Ambit Biosciences Corporation primarily develops targeted therapies for oncology and inflammatory diseases, with quizartinib as its flagship product. This selective FMS-like tyrosine kinase 3 (FLT3) inhibitor is designed to treat acute myeloid leukemia (AML) and is administered orally once daily. The company also develops other small molecule kinase inhibitors aimed at addressing unmet medical needs in oncology and autoimmune diseases, serving various healthcare institutions and professionals globally, particularly in North America, Europe, and Asia.In the most recent fiscal year of 2013, Ambit Biosciences generated revenue of USD 27.09 mn, with an EBITDA of USD -6.66 mn. Revenue streams are bolstered by licensing agreements and collaborations with pharmaceutical companies and clinical trial sponsors.Ambit Biosciences plans to utilize the funds from its most recent acquisition to support the development and launch of new products and expand into new geographic markets. The focus will be on bolstering its pipeline of oncology therapies. The acquisition by Daiichi Sankyo in September 2014 is expected to facilitate entry into new markets, leveraging Daiichi Sankyo's global reach and resources. The company's strategic initiatives aim to enhance its offerings in oncology and inflammatory diseases, aligning with the trends of growing demand for innovative cancer therapies.

## Funding rounds

- Series E, May 1, 2013, $25M — Forward Ventures, OrbiMed Advisors, GrowthWorks Capital, Gimv, Radius Ventures, Aisling Capital, Apposite Capital, MedImmune Ventures, Roche Venture Fund
- Series E, Nov 6, 2012, $25M — Forward Ventures, OrbiMed Advisors, GrowthWorks Capital, Gimv, Radius Ventures, Aisling Capital, Apposite Capital, MedImmune Ventures, Roche Venture Fund
- Series D, Jun 10, 2011, $22M — Forward Ventures, OrbiMed Advisors, Perseus, GrowthWorks Capital, Gimv, Radius Ventures, GeneChem, Apposite Capital, MedImmune Ventures, NovaQuest Capital Management, Horizon Technology Finance Corporation, Roche Venture Fund
- Series D, Nov 14, 2007, $46M — Forward Ventures, OrbiMed Advisors, Perseus, Avalon Ventures, Gimv, Radius Ventures, GeneChem, Aisling Capital, Apposite Capital, MedImmune Ventures, NovaQuest Capital Management, Horizon Technology Finance Corporation, Roche Venture Fund, Canadian Medical Discoveries Fund Inc.
- Series C, May 12, 2005, $10M — Forward Ventures, Perseus, Avalon Ventures, Gimv, GeneChem, Roche Venture Fund, Canadian Medical Discoveries Fund Inc.
- Series C, Aug 1, 2004, $21M — Forward Ventures, Perseus, Avalon Ventures, Gimv, GeneChem, Roche Venture Fund, Canadian Medical Discoveries Fund Inc.
- Series B, Nov 7, 2001, $10M — Forward Ventures, Perseus, Avalon Ventures, Baker-Tisch Investments

## Investors

- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series B, Series C, Series D, Series E
- Perseus (https://capitalatlas.ai/funds/perseus) — Series B, Series C, Series D
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series B, Series C, Series D
- Baker-Tisch Investments — Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series C, Series D, Series E
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series C, Series D
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series C, Series D, Series E
- Canadian Medical Discoveries Fund Inc. — Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D, Series E
- Radius Ventures (https://capitalatlas.ai/funds/radius-ventures) — Series D, Series E
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series D, Series E
- Apposite Capital (https://capitalatlas.ai/funds/apposite-capital) — Series D, Series E
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series D, Series E
- NovaQuest Capital Management (https://capitalatlas.ai/funds/novaquest-capital-management) — Series D
- Horizon Technology Finance Corporation — Series D
- GrowthWorks Capital (https://capitalatlas.ai/funds/growthworks-capital) — Series D, Series E